Active Filter(s):
Details:
Under the terms of their collaboration agreement, Orchestra BioMed and Terumo plan to execute a global clinical program Virtue SAB (sirolimus), in an effort to gain regulatory approval for commercial sale of Virtue SAB in multiple markets and indications.
Lead Product(s): Sirolimus
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Virtue SAB
Highest Development Status: Undisclosed Product Type: Small molecule
Recipient: Orchestra Biomed
Deal Size: Undisclosed Upfront Cash: $30.0 million
Deal Type: Collaboration July 05, 2022